TrialRMD open2019

Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54.

Rieke Alten et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.